comparemela.com

Page 33 - Smb News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pherecydes Pharma Announces the Positive Recommendation of the DSMB For the Continuation of Its Phase II Clinical Study PhagoDAIR in Osteoarticular Infections Caused by Staphylococcus aureus

Regulatory News: Pherecydes Pharma (FR0011651694 ALPHE, eligible for PEA-PME equity savings plans) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant

StoneCo doubles profitability and grows revenue by 71% to R$ 2 5 billion in 3Q22

R$ 211 million adjusted EBT up +97% over 2Q22, exceeding guidance by 69% With net addition of 248,000 MSMB clients in 3Q22, company accelerates its growth and reaches 2.4 million clients, with. | November 17, 2022

vimarsana © 2020. All Rights Reserved.